Jennifer oversees a team that delivers reimbursement strategy and health policy consulting for pharmaceutical, biotechnology, and medical device clients. She analyzes the environment to provide strategic guidance on how to best navigate today’s most pressing coverage and access challenges. Jennifer is an experienced Healthcare Executive with expertise in access and reimbursement, Medicare, managed care, evidence-based medicine and the pharmaceutical and biotechnology marketplace. She has strong analytic skills to creatively solve complex problems and explain their solutions.
The arrival of pharmacy benefit biosimilars, particularly in the form of self-administered adalimumab biosimilars, could lead to much more negotiating activity between payers and physicians, who would become primarily prescribers of these products, rather than administrators.21 December 2021